Treats candidemia and invasive candidiasis. Sold as Rezzayo. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Rezafungin Acetate (sold as Rezzayo), first approved Mar 22, 2023, with 1 new use approved and 0 published complete response letters.
| Rezzayo | Part B | $2.9M | +161% | 245 |
| Rezzayo | Part D | $670K | +317% | 58 |
| Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment OptionsChronic Pulmonary Aspergillosis · Mundipharma Research Limited | Phase 2 | Active, not recruiting | Jan 27, 2025 |
| Rezafungin for Treatment of Pneumocystis Pneumonia in HIV AdultsPneumocystis Pneumonia · Mundipharma Research Limited | Phase 2 | Recruiting | Apr 28, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Mar 22, 2023 | RezzayoNDA 217417 · New molecular entity | Mundipharma | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
